Gantenerumab Reduces Amyloid Levels in Alzheimer's Patients

A study demonstrates that two to seven months of treatment with gantenerumab led to dose-dependent amyloid reduction in the brains of patients with Alzheimer's disease.

Researchers from the F. Hoffmann-La Roche Ltd., Neuroscience in Basel, Switzerland said the medication gantenerumab appeared to reduce brain amyloid levels in patients with Alzheimer's disease, according to a preliminary study they had performed.

The study involved study subjects, who had mild-to-moderate Alzheimer's disease, at three university medical centers.

Two consecutive groups of patients were randomized to receive two to seven infusions of intravenous gantenerumab -- 60 mg or 200 mg -- or placebo every four weeks. Additionally, brain tissue from two patients who had Alzheimer's disease -- tissue obtained during tumor surgery -- was examined.